Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisbon, Portugal.
Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisbon, Portugal; Department of Biochemistry and Human Biology, Faculty of Pharmacy, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisbon, Portugal.
Mol Cell Neurosci. 2019 Apr;96:1-9. doi: 10.1016/j.mcn.2019.01.003. Epub 2019 Feb 13.
Parkinson's disease (PD) is a progressive neurological disorder, mainly characterized by the progressive loss of dopaminergic neurons in the Substantia nigra pars compacta (SNpc) and by the presence of intracellular inclusions, known as Lewy bodies. Despite SNpc being considered the primary affected region in PD, the neuropathological features are confined solely to the nigro-striatal axis. With disease progression other brain regions are also affected, namely the cerebral cortex, although the spreading of the neurologic damage to this region is still not completely unraveled. Tauroursodeoxycholic acid (TUDCA) is an endogenous bile acid that has been shown to have antioxidant properties and to exhibit a neuroprotective effect in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mice model of PD. Moreover, TUDCA anti-inflammatory properties have been reported in glial cells, making it a prominent therapeutic agent in PD. Here, we used C57BL/6 mice injected with MPTP in a sub-acute paradigm aiming to investigate if the neurotoxic effects of MPTP could be extended to the cerebral cortex. In parallel, we evaluated the anti-oxidant, neuroprotective and anti-inflammatory effects of TUDCA. The anti-inflammatory mechanisms elicited by TUDCA were further dissected in microglia cells. Our results show that MPTP leads to a decrease of ATP and activated AMP-activated protein kinase levels in mice cortex, and to a transient increase in the expression of antioxidant downstream targets of nuclear factor erythroid 2 related factor 2 (Nrf-2), and parkin. Notably, MPTP increases pro-inflammatory markers, while down-regulating the expression of the anti-inflammatory protein Annexin-A1 (ANXA1). Importantly, we show that TUDCA treatment prevents the deleterious effects of MPTP, sustains increased levels of antioxidant enzymes and parkin, and most of all negatively modulates neuroinflammation and up-regulates ANXA1 expression. Additionally, results from cellular models using microglia corroborate TUDCA modulation of ANXA1 synthesis, linking inhibition of neuroinflammation and neuroprotection by TUDCA.
帕金森病(PD)是一种进行性神经退行性疾病,主要特征是黑质致密部(SNpc)中的多巴胺能神经元进行性丧失,以及存在称为路易体的细胞内包涵体。尽管 SNpc 被认为是 PD 的主要受累区域,但神经病理学特征仅限于黑质纹状体轴。随着疾病的进展,其他大脑区域也会受到影响,即大脑皮层,尽管神经损伤向该区域的扩散尚未完全阐明。牛磺熊脱氧胆酸(TUDCA)是一种内源性胆酸,已被证明具有抗氧化特性,并在 1-甲基-4-苯基-1,2,3,6-四氢吡啶(MPTP)PD 小鼠模型中表现出神经保护作用。此外,TUDCA 在神经胶质细胞中的抗炎特性已被报道,使其成为 PD 的一种重要治疗药物。在这里,我们使用 C57BL/6 小鼠注射 MPTP 进行亚急性实验,旨在研究 MPTP 的神经毒性是否会扩展到大脑皮层。同时,我们评估了 TUDCA 的抗氧化、神经保护和抗炎作用。TUDCA 引发的抗炎机制在小神经胶质细胞中进一步剖析。我们的结果表明,MPTP 导致小鼠皮层中 ATP 减少和 AMP 激活蛋白激酶水平升高,并导致核因子红细胞 2 相关因子 2(Nrf-2)和 parkin 的抗氧化剂下游靶标表达短暂增加。值得注意的是,MPTP 增加了促炎标志物,同时下调了抗炎蛋白 Annexin-A1(ANXA1)的表达。重要的是,我们表明 TUDCA 治疗可预防 MPTP 的有害作用,维持抗氧化酶和 parkin 的升高水平,最重要的是,负性调节神经炎症并上调 ANXA1 的表达。此外,使用小神经胶质细胞的细胞模型的结果证实了 TUDCA 对 ANXA1 合成的调节,将 TUDCA 对神经炎症和神经保护的抑制作用联系起来。